Endocrinology

New ADA 2026 analyses show Afrezza delivered comparable glycemic control, favorable safety, and higher treatment satisfaction in youth.

This decision marks the first FDA-approved inhaled insulin for pediatric patients.

An international consensus group has recommended renaming PCOS to PMOS to better reflect the condition’s endocrine and metabolic features.

Two-year data from the pivotal ApproaCH trial showed sustained growth improvements with TransCon CNP in pediatric achondroplasia.

FDA approved insulin glargine-aldy as an interchangeable biosimilar to Lantus for type 1 diabetes and adult type 2 diabetes.

Phase 3 sunRIZE trial of ersodetug in congenital hyperinsulinism missed its primary endpoint but showed CGM-based glycemic gains.

Two-year CAHtalyst data show crinecerfont sustains androgen reduction and lowers glucocorticoid doses in children with congenital adrenal hyperplasia.

FDA expands teplizumab (Tzeld) use to children as young as 1 year with stage 2 type 1 diabetes, aiming to delay progression to clinical disease.

Updated guidance outlines triglyceride thresholds that distinguish ASCVD vs pancreatitis risk and inform targeted management strategies in children.

Get caught up with Contemporary Pediatrics! This list helps you navigate our top stories from the week, all in one place.

FDA okays once-weekly navepegritide for children with achondroplasia, boosting growth with strong trial data; rollout expected early Q2 2026.

With the priority review, the Prescription Drug User Fee Act date is set for April 29, 2026, for potential approval in this younger indication.

Ferric maltol is now an FDA-approved oral iron therapy for both adults and adolescents with iron deficiency, aged 10 years and older.

Experts discussed how the 3-stage model reframed type 1 diabetes as a condition that could be detected through earlier screening.

This introductory Special Report episode outlines how advances in staging and early detection are reshaping pediatric approaches to type 1 diabetes.

Jonathan Flyer, MD, discusses how the LEAD Pediatric Initiative is addressing persistently low rates of universal pediatric lipid screening.

See the full case of our most recent puzzler quiz, and view the correct diagnosis of this slender teen with a growing abdomen and shrinking height.

Jonathan Flyer, MD, emphasizes that early detection of FH through guideline-recommended universal screening can be lifesaving and supports broader family identification.

Jonathan Flyer, MD, highlights strategies to improve universal pediatric lipid screening and early detection of familial hypercholesterolemia in children.

Explore groundbreaking therapies for type 1 diabetes that aim to delay onset, preserve β-cell function, and restore insulin independence.

From another potential treatment for pediatric atopic dermatitis, to STI therapy for uncomplicated urogenital gonorrhea, take a look ahead at key PDUFA dates in Q4.

The Phase 3 SURPASS-PEDS trial found tirzepatide improved glycemic control and weight outcomes in youth-onset type 2 diabetes, with benefits lasting one year.

Panelists discuss how central precocious puberty involves early activation of the hypothalamic-pituitary-gonadal axis before age 8 in girls and age 9 in boys. This requires individualized treatment decisions based on factors such as growth velocity, bone age advancement, and psychosocial impact, with GnRH agonist therapies available in multiple formulations (injections and implants) that effectively suppress puberty while preserving final height potential and have reassuring long-term safety profiles for bone health and fertility outcomes.

Michael Haller, MD, tell providers they shouldn't be surprised if more children with T1D use inhaled insulin.